Fig. 7: Comparison of the performance of transcriptomic signatures with our best transcriptomic and multimodal models. | Nature Communications

Fig. 7: Comparison of the performance of transcriptomic signatures with our best transcriptomic and multimodal models.

From: Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer

Fig. 7

Comparison of the performance of 36 transcriptomic signatures previously associated with immunotherapy (from the literature) against the best unimodal transcriptomic model and the best multimodal model from our analysis for each prediction task. The bar height corresponds to the performance metric (either ROC AUC or C-index), averaged across 100 cross-validation schemes and estimated for the 80 patients with a complete multimodal profile. The error bar indicates ± 1 standard deviation (for signatures without a training step, this standard deviation is zero). Performance metrics were transformed using max(x, 1-x) to account for signatures with a performance below 0.5. Blue bars represent performances below 0.5 (higher signature values are associated with better prognosis), while red bars represent performances above 0.5 (higher signature values are associated with worse prognosis). A Comparison for 1-year death prediction (n = 77 patients with a complete profile and available 1-year death label) and OS prediction (n = 79 patients with complete profile and available OS information). B Comparison for 6-month progression prediction (n = 75 patients with complete profile and available 6-month progression label) and PFS prediction (n = 80 patients with complete profile and available PFS information). Source data are provided as a Source Data file.

Back to article page